美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

Ipsen S.A.

40.46

+0.22000.55%

成交量：4,579.00

成交額：18.59萬

市值：133.68億

市盈率：18.53

高：40.69

開：40.69

低：40.46

收：40.24

52周最高：42.10

52周最低：25.11

股本：3.30億

流通股本：1.12億

量比：13.49

換手率：0.00%

股息：0.42

股息率：1.03%

每股收益(TTM):2.18

每股收益(LYR):2.15

淨資產收益率：10.89%

總資產收益率：9.58%

市淨率：2.65

市盈率(LYR):18.80

資料載入中...

總覽公司新聞資訊公告

概念

no data

沒有相關數據

資金流向

資金流入：

資金流出：

新聞資訊

益普生公布2025年上半年強勁業績並上調全年財務指引

益普生2025年第一季度實現穩健業績增長並確認全年業績指引

在所有治療領域強勁業績的推動下，益普生2024年實現穩健業績增長並確認2025年全年指引

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎證券香港 | 輕鬆買賣美股港股A股/美債/ETF/Crypto/期權期貨","description":"老虎證券香港提供多種優惠: 港股&Crypto 0佣0平台費、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","keywords":"老虎證券,老虎證券開戶,老虎證券香港,老虎證券投資,老虎證券美股,老虎證券登錄,證券開戶,證券公司開戶,股票開戶,香港證券公司,香港證券,證券公司,美股投資平台,小額投資理財,投資app,投資平台,股票買賣,買賣股票平台,炒股app,證券app,新手投資","social":{"ogDescription":"老虎證券香港提供多種優惠: 港股&Crypto 0佣0平台費、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/IPSEY"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"IPSEY","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IPSEY\",,,,,undefined,":{"symbol":"IPSEY","market":"US","secType":"STK","nameCN":"Ipsen S.A.","latestPrice":40.46,"timestamp":1770670800000,"preClose":40.24,"halted":0,"volume":4579,"delay":15,"changeRate":0.005467196819085459,"floatShares":112371575,"shares":330397936,"eps":2.183055,"marketStatus":"未開盤","change":0.22,"latestTime":"02-09 16:00:00 EST 延時","open":40.69,"high":40.69,"low":40.46,"amount":185932.74,"amplitude":0.005716,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"otc":true,"ttmEps":2.183055,"tradingStatus":0,"nextMarketStatus":{"tag":"盤前交易","tradingStatus":1,"beginTime":1770714000000},"marketStatusCode":0,"adr":0,"adrRate":0.25,"exchange":"PINK LIMITED","adjPreClose":40.24,"volumeRatio":13.491462},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IPSEY\",,,,,undefined,":{"symbol":"IPSEY","floatShares":112371575,"roa":"9.58%","roe":"10.89%","lyrEps":2.152613,"volumeRatio":13.491462,"shares":330397936,"dividePrice":0.416815,"high":40.69,"amplitude":0.005716,"preClose":40.24,"low":40.46,"week52Low":25.11,"pbRate":"2.65","psRate":"2.99","week52High":42.1025,"institutionHeld":0,"latestPrice":40.46,"eps":2.183055,"divideRate":0.010302,"volume":4579,"delay":15,"ttmEps":2.183055,"open":40.69,"prevYearClose":36.3596,"prevWeekClose":40.24,"prevMonthClose":40.76,"prevQuarterClose":36.3596,"fiveDayClose":40.24,"twentyDayClose":36.8,"sixtyDayClose":37.58},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/IPSEY\",params:#limit:5,,,undefined,":[{"date":"2025-06-09","symbol":"IPSEY","amount":0.398618,"announcedDate":"2025-05-28","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-06-09","defaultRemindTime":1749475800000,"name":"Ipsen S.A.","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-06-25","payableDate":"2025-06-09","currency":"USD","dateTimestamp":1749441600000,"payDate":"2025-06-25"},{"date":"2024-07-25","symbol":"IPSEY","type":"earning","reportTimeType":"","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1721894400000,"name":null,"time":"","dateTimestamp":1721880000000,"actualEps":null},{"date":"2024-05-31","symbol":"IPSEY","amount":0.235267,"announcedDate":"2024-05-20","type":"dividend","market":"US","newRecordDate":"2024-05-31","defaultRemindTime":1717162200000,"name":"Ipsen S.A.","recordDate":null,"payableDate":"2024-05-31","currency":"USD","dateTimestamp":1717128000000,"payDate":null},{"date":"2023-06-02","symbol":"IPSEY","amount":0.324045,"announcedDate":"2023-05-19","type":"dividend","market":"US","newRecordDate":"2023-06-05","defaultRemindTime":1685712600000,"name":"Ipsen S.A.","recordDate":"2023-06-27","payableDate":"2023-06-05","currency":"USD","dateTimestamp":1685678400000,"payDate":"2023-06-27"},{"market":"US","date":"2022-10-26","symbol":"IPSEY","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"盤前","type":"earning","dateTimestamp":1666756800000,"reportTimeType":"pre","actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"IPSEY\",market:\"US\",,,undefined,":[{"executeDate":"2016-05-31","recordDate":"2016-06-02","paymentDate":"2016-07-13","value":0.177552,"currency":"USD"},{"executeDate":"2021-05-28","recordDate":"2021-06-01","paymentDate":"2021-06-09","value":0.275217,"currency":"USD"},{"executeDate":"2022-05-31","recordDate":"2022-06-01","paymentDate":"2022-06-09","value":0.315063,"currency":"USD"},{"executeDate":"2023-06-02","recordDate":"2023-06-05","paymentDate":"2023-06-27","value":0.324045,"currency":"USD"},{"executeDate":"2024-05-31","recordDate":"2024-05-31","paymentDate":null,"value":0.235267,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"IPSEY\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"IPSEY\",pageSize:4,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2557399040","title":"益普生公布2025年上半年強勁業績並上調全年財務指引","url":"https://stock-news.laohu8.com/highlight/detail?id=2557399040","media":"美通社","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2557399040?lang=zh_tw&edition=fundamental","pubTime":"2025-08-05 12:32","pubTimestamp":1754368320,"startTime":"0","endTime":"0","summary":"在此基础上，我很高兴，益普生在销售和利润方面的全年指引做了上调。\" 2025年全年指引 基于上半年强劲的业绩表现，益普生上调了2025年全年财务指引：  以固定汇率计算，总销售额增长超过7.0%。2025年7月23日，欧盟委员会批准益普生将Cabometyx用于治疗既往接受治疗的晚期神经内分泌肿瘤患者。上述所有风险因素均可能影响益普生未来达成财务目标的能力，而这些目标是基于当前可获取信息并假设宏观经济环境相对稳定的前提下设定的。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/4744400_ZH44400_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["IPSEY","BK4007","IPN"],"gpt_icon":0},{"id":"2528906912","title":"益普生2025年第一季度實現穩健業績增長並確認全年業績指引","url":"https://stock-news.laohu8.com/highlight/detail?id=2528906912","media":"美通社","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2528906912?lang=zh_tw&edition=fundamental","pubTime":"2025-04-18 17:35","pubTimestamp":1744968900,"startTime":"0","endTime":"0","summary":"确认2025年全年财务指引。巴黎2025年4月18日 /美通社/ -- 全球特药领域生物制药公司益普生于4月16日公布了2025年第一季度的财务业绩。对益普生而言，2025年将是重要的一年，多个产品即将上市，我们的产品组合有望达成多项里程碑。\" 全年指引 益普生确认了2025年全年财务指引：  以固定汇率计算，总销售额增长超过5.0%。集团再融资 益普生于3月19日宣布成功完成其首次5亿欧元的评级公募债券发行，票面利率为3.875%，于2032年3月到期。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/4667912_ZH67912_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["IPN","BK4007","IPSEY"],"gpt_icon":0},{"id":"2512529945","title":"在所有治療領域強勁業績的推動下，益普生2024年實現穩健業績增長並確認2025年全年指引","url":"https://stock-news.laohu8.com/highlight/detail?id=2512529945","media":"美通社","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512529945?lang=zh_tw&edition=fundamental","pubTime":"2025-02-17 17:58","pubTimestamp":1739786280,"startTime":"0","endTime":"0","summary":"本年度还与Skyhawk Therapeutics签署了一项合作协议，开发用于治疗罕见神经系统疾病的RNA调节小分子药物。环境、社会和治理 2024年，益普生采取了重要步骤，以实施可持续发展战略的宏伟目标。经过密集转型项目，目前益普生全球99.8%的电力来自可再生能源。2025年财务指引 益普生为2025财年制定了以下财务指引，其中排除了潜在的后期业务开发交易的任何影响：  以固定汇率计算，总销售额增长超过5.0%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/4620551_ZH20551_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["BK4139","IPSEY","ADC","ALGS","IPN","BK4505","BK4231","BK4007","BK4080"],"gpt_icon":0}],"pageSize":4,"totalPage":1,"pageCount":1,"totalSize":3,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/IPSEY\",params:#limit:6,delay:false,,,undefined,":[]}}